Ujjal Didar Singh Sekhon/LinkedIn
Jul 28, 2026, 08:28
Ujjal Didar Singh Sekhon: Exploring SynthoPlate Under P2Y12 Blockade
Ujjal Didar Singh Sekhon, Director of Research Development at Haima Therapeutics, shared a post on LinkedIn:
“ISTH 2026 was a privilege to be part of: pathbreaking research, illuminating conversations, and a dose of Paris on top.
I was honored to present our work advancing SynthoPlate through models of P2Y12 blockade.
A huge thanks to the Haima team behind this milestone, and to the colleagues who came by with questions and suggestions that will sharpen what comes next.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation
-
Nov 8, 2026, 05:34Eugene Bolotin: Thrombosis and Survival in Pancreatic Cancer